Catégorie : Cannabis et santé mentale

Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects ?, H. Valerie Curran et a., 2018

Which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like effects ? H. Valerie Curran, Chandni Hindocha, Celia J. A. Morgan, Natacha Shaban, Ravi K. Das and Tom P. Freeman Psychological Medicine, 2018, 1-7. https://doi.org/10.1017/S003329171800226X Abstract Background : Changes in cannabis regulation globally make it increasingly important to determine what predicts an individual’s risk of experiencing adverse drug effects. Relevant studies have used diverse self-report measures of cannabis use, and few include multiple biological measures. Here we aimed to determine which biological and self-report measures of cannabis use predict cannabis dependency and acute psychotic-like symptoms. Method : In a naturalistic study, 410 [...]

Lire la suite

Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment, Amir Englund et al., 2012

Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment Amir Englund, Paul D Morrison, Judith Nottage, Dominic Hague, Fergus Kane1, Stefania Bonaccorso1, James M Stone, Avi Reichenberg, Rudolf Brenneisen, David Holt, Amanda Feilding, Lucy Walker, Robin M Murray and Shitij Kapur Journal of Psychopharmacology, 2012 Doi : 10.1177/0269881112460109 Abstract Community-based studies suggest that cannabis products that are high in Δ9-tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment with CBD inhibited [...]

Lire la suite

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia, F. M. Leweke et al., 2012

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia F. M. Leweke, D. Piomelli, F. Pahlisch, D. Muhl, C.W. Gerth, C. Hoyer, J. Klosterkötter, M. Hellmich and D. Koethe Translationnal Psychiatry, 2012, 2, e94 doi :10.1038/tp.2012.15; published online 20 March 2012 Abstract Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. We previously reported that an elevation of anandamide levels in cerebrospinal fluid inversely correlated to psychotic symptoms. Furthermore, enhanced anandamide signaling let to a lower transition rate from initial prodromal states into frank psychosis as well as postponed transition. In [...]

Lire la suite

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders, Alline Cristina Campos et al., 2012,

Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders Alline Cristina Campos, Fabricio Araujo Moreira, Felipe Villela Gomes, Elaine Aparecida Del Bel and Francisco Silveira Guimaraes Philosophical Transactions of The Royal Society Bulletin, 2012, 367, 3364–3378 doi:10.1098/rstb.2011.0389 Abstract Cannabidiol (CBD) is amajor phytocannabinoid present in the Cannabis sativa plant. It lacks the psychotomimetic and other psychotropic effects that the main plant compound D9 tetrahydrocannabinol (THC) being able, on the contrary, to antagonize these effects. This property, together with its safety profile, was an initial stimulus for the investigation of CBD pharmacological properties. It is now clear thatCBDhas therapeutic potential over a [...]

Lire la suite

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia : A Multicenter Randomized Controlled Trial, Philip Mc Guire et al., 2018

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia : A Multicenter Randomized Controlled Trial Philip Mc Guire, Philip Robson, Wieslaw Jerzy Cubala, Daniel Vasile, Paul Dugald Morrison, Rachel Barron, Adam Taylor, Stephen Wright, American Journal of Psychiatry, 2018, 175, 3, 225-231 https://doi.org/10.1176/appi.ajp.2017.17030325 Abstract Objective: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. Method: In an exploratory double-blind parallel-group trial, patients with schizophrenia were randomized in a 1:1 ratio to receive CBD (1000 mg/day; N=43) or placebo (N=45) alongside their existing antipsychotic medication. Participants were assessed before and after treatment using [...]

Lire la suite

CANNABIS EN TÊTE, “Dopamine”, Mai 2019

CANNABIS EN TÊTE A propos du Dossier Central publié dans le N°237 de la Revue SANTÉ MENTALE "SCHIZOPHRÉNIE ET CANNABIS" - - - - - - - - - - DOPAMINE #05 (MAI 2019)   Sans créer de lien de causalité à la vas-vite, difficile de ne pas associer schizophrénie et usage de cannabis puisqu'un quart des patients souffrants de cette pathologie consomment régulièrement un produit qui n'est peut-être pas entré dans leur vie par hasard ou du moins qu'ils ont adopté pour soulager certains symptômes tout en en aggravant d'autres... Quant à la part de responsabilité du cannabis dans l'apparition d'une schizophrénie, un certain nombre [...]

Lire la suite

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug, A.W. Zuardi et al., 2006

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug A.W. Zuardi, J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira and F.S. Guimarães Brazilian Journal of Medical and Biological Research, 2006, 39, 421-429 ISSN 0100-879X Review Abstract A high dose of Δ9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of Δ9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent which is devoid of the typical effects of the plant. This observation led us to suspect that CBD could have anxiolytic and/or antipsychotic actions. Studies in animal models and in healthy volunteers clearly suggest an anxiolytic-like effect of CBD. The [...]

Lire la suite

Dissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity, Matthew B Wall et al.,

Dissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity Matthew B. Wall, Rebecca Pope, Tom P. Freeman, Oliwia S. Kowalczyk, Lysia Demetriou, Claire Mokrysz, Chandni Hindocha, Will Lawn, Michael A.P. Bloomfield, Abigail M. Freeman, Amanda Feilding, David J. Nutt and H. Valerie Curran Journal of Psychopharmacology,  2019, 1–9 DOI: 10.1177/0269881119841568 journals.sagepub.com/home/jop   Abstract Background : Two major constituents of cannabis are Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the main psychoactive component; CBD may buffer the user against the harmful effects of THC. Aims : We examined the effects of two strains of cannabis and placebo on the human brain’s resting-state networks [...]

Lire la suite

A role for cannabidiol in psychiatry? Keep calm and follow the drug development rules, Gabriella Gobbi, 2019

A role for cannabidiol in psychiatry? Keep calm and follow the drug development rules Gabriella Gobbi THE WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2019, VOL. 20, NO. 2, 98–100 Commentary https://doi.org/10.1080/15622975.2019.1584680   Along with tetrahydrocannabinol (THC), cannabidiol (CBD) is one of the main pharmacological components of Cannabis sativa and indica. Unlike THC, which binds CB1 receptors, CBD does not cause any dependence, and acts mostly via 5-HT1A and TPRV1 receptors (De Gregorio et al. 2018). Khoury et al. (2019) recently published a systematic review on the role of cannabidiol in psychiatry in the World Journal of Biological Psychiatry. After analysing 609 articles, they found six case reports, [...]

Lire la suite